Imunon IMNN
NASDAQ IMNN
$1.32 +0.03 (+2.33%)
At close: Oct 1, 2026 · 4:00 PM EDT

Imunon (IMNN) Accumulated Depreciation (2012 - 2025)

Updated

Imunon (IMNN) reported Accumulated Depreciation of $1.28 million for Q4 2025, up 6.7% from $1.2 million a year earlier.

Analysis

Imunon (IMNN) Accumulated Depreciation (2012 - 2025) Analysis & Trends

Dating back to Q4 2012, Imunon's Accumulated Depreciation record includes 13 quarters.

  • Accumulated Depreciation has a five-year compound annual growth rate of -16.9% (FY2020 to FY2025).
  • By year, Accumulated Depreciation came in at $1.2 million in FY2024 (-43.1%), $2.1 million in FY2023 (-20.5%), $2.64 million in FY2022 (-21.2%) and $3.36 million in FY2021 (+4.0%).
  • The Q4 2025 figure ranks as the highest quarterly Accumulated Depreciation since Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Imunon 6.02 Mn 6.02 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.28 Mn
Dec 31, 2024 1.20 Mn
Dec 31, 2023 2.10 Mn
Dec 31, 2022 2.64 Mn
Dec 31, 2021 3.36 Mn
Dec 31, 2020 3.23 Mn
Dec 31, 2019 3.10 Mn
Dec 31, 2018 2.97 Mn
Dec 31, 2017 2.84 Mn
Dec 31, 2016 2.51 Mn
Dec 31, 2015 2.06 Mn
Dec 31, 2013 1.26 Mn
Dec 31, 2012 924,961.00
API Access

Imunon Accumulated Depreciation API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-depreciation&ticker=IMNN&period=max&api_key=YOUR_API_KEY